Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Monday's Bonus Article Oklo: The Bottom Is In, and the Upside Potential Is NuclearSubmitted by Thomas Hughes. Article Published: 3/19/2026. 
Key Points - Oklo's FY2025 update revealed progress, and the market liked it; the diversification strategy is progressing.
- Analysts responded favorably, affirming the forecast for a 50% stock price increase.
- Short-covering and institutional accumulation align with a technical bottom, setting this market up to sustain a rebound in 2026.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Oklo Inc. (NYSE: OKLO) still faces headwinds, including a lack of revenue and profits, but the market appears unconcerned. The company's fiscal year 2025 (FY2025) progress report and recent updates show it is on track to meet long-term goals and market expectations. The market response — including analyst updates after the release — makes the point: near-term revenue isn't the primary focus given the perceived long-term opportunity. Analysts Focus on Oklo's Long-Term Opportunity MarketBeat tracked roughly half a dozen analyst revisions within the first 12 hours after the release. Those included a single price-target reduction that was offset by a larger number of affirmed ratings and targets, with no downgrades reported. Newmont, the world's largest gold miner, doubled over the past year — beating Apple, Nvidia, Meta, Tesla, Amazon, and Google. And more than two dozen smaller names have done even better. JC Parets calls it the "Chaos Cycle," a 135-year-old pattern where overlooked real-asset stocks quietly deliver the biggest gains in decades. He just recorded an urgent briefing on what's driving this shift — including one stock name he's giving away free. Go here for JC's full briefing The broader takeaway: analyst activity is consistent with an expanding coverage base, a steady Moderate Buy consensus, a 58% Buy-side bias, and an upward trend in price targets. Those targets are notable because consensus implies more than 50% upside relative to mid-March lows. Analysts did express concern about the 2025 results, but they remain primarily focused on the long-term opportunity and progress with Nuclear Regulatory Commission licensing. Oklo received its first license through its subsidiary Atomic Alchemy, which produces isotopes. The license permits the receiving, possession, storage, processing, repackaging, and distribution of up to two curies of radium-226—roughly two grams. Two grams is not much, and radium-226 has limited standalone value; it was once commonly used in medical applications but is now difficult and costly to handle and remediate. Still, demand for this rare isotope is rising because it can serve as a source material for actinium, which is used in specialized cancer treatments. Actinium is among the most expensive elements, with some therapies costing roughly $20,000 per dose. For investors, the license supports Oklo's diversification strategy and opens a potential revenue stream. It may take a few quarters for meaningful revenue to appear, but it could arrive well before the commercialization of Oklo's core nuclear reactor technologies. Institutional and Short-Selling Data Suggest the Bottom May Be In Institutional and short-selling data point toward a potential bottom for Oklo's stock. Short interest remains elevated—near 15% as of early March—but it has declined from its peak around the stock's October 2025 high and may continue to fall in upcoming reports. Institutional activity moved in the opposite direction, ramping up after Oklo's Q2 2025 plunge and reaching record levels in early 2026. Institutional investors now own roughly 85% of the shares, which provides significant support; they have been net buyers at a pace of about $3 purchased for every $1 sold. If those trends persist, the available float could shrink materially over the coming months, making upward price moves more likely. A significant positive catalyst could also trigger a short squeeze. Dilution Eases in 2026 Shareholder dilution was a major factor in 2025, but the pressure should ease in 2026. The company's share count rose about 50% year-over-year, and the balance sheet appears well capitalized. FY2026 plans indicate sufficient capital to fund the current project burn rate for roughly two years, creating a window for secondary revenue streams—like the isotope business—to develop. The trade-off is that Oklo does not expect profitability until around 2030, which implies additional capital will likely be required down the road. The technical setup is encouraging. OKLO's stock is well off its highs and showed an overextended sell-off by March. The MACD has turned bullish and the stochastic oscillator is signaling a strong buy at current levels. Whether the market follows through on these technical signals remains to be seen, and it may take time for momentum to build. Fundamentally, the lack of revenue and profits remains a substantial hurdle. The primary risk is execution and potential delays. The market appears to be pricing a robust growth outlook—valuing the stock at over 100 times its initial-year earnings—and may react sharply to timeline setbacks. That means Oklo could remain volatile even as the recovery story unfolds. | 
